
Loading, please wait...

Loading, please wait...
"Wherever the art of Medicine is loved, there is also a love of Humanity."
Hippocrates

Healthcare providers rely heavily on POC glucose meter accuracy to guide critical bedside decisions. However, a recent study involving large inpatient cohorts from Australia and the United States suggests that real-world performance often diverges from manufacturer claims. Researchers analyzed retrospective data to compare point-of-care (POC) devices against laboratory and blood gas methods. The results indicate that systematic biases exist within routine hospital settings, particularly during extremes of glycaemia.
The study found that POC meters frequently exhibit a predictable pattern of error. Specifically, these devices showed a positive bias at lower glucose levels and a negative bias at higher concentrations. While most results remained within clinically "safe" zones on standard error grids, they often failed to meet strict ISO or FDA numerical targets. Consequently, clinicians should interpret POC results with caution when they fall outside normal ranges. Furthermore, blood gas measurements proved to be a much more reliable practical comparator to laboratory gold standards than handheld meters.
One of the most significant findings involves the influence of physiological variables. The research highlighted that low haemoglobin levels significantly amplify negative bias at higher glucose stages. Because anaemia is prevalent among hospitalised patients, this discovery has direct implications for inpatient management. In addition, variations in partial pressure of oxygen (pO2) did not show a consistent impact on meter performance. Therefore, clinicians must consider a patient's haematocrit level when evaluating suspicious glucose readings.
To improve patient safety, hospitals should implement local validation protocols for their glucose monitoring systems. If a POC result seems inconsistent with a patient's clinical presentation, the staff must perform confirmatory laboratory testing. Moreover, narrowing the time window between POC and lab measurements can help identify these discrepancies more effectively. By recognizing the limitations of bedside technology, medical teams can better avoid potential dosing errors and improve overall glycaemic control.
Low haemoglobin or haematocrit levels can cause a negative bias in many POC glucose meters, especially at high blood sugar levels. This means the meter might show a lower result than the actual laboratory glucose concentration.
Yes, the study indicated that blood gas measurements closely parallel laboratory gold standards. Therefore, they serve as a more reliable practical alternative for monitoring critically ill patients compared to standard handheld POC meters.
You should always verify suspicious or extreme POC results with a formal laboratory glucose test. This step is crucial for ensuring accurate diagnosis and preventing inappropriate insulin or glucose administration.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Always seek the advice of a qualified healthcare provider regarding any medical condition or treatment. Refer to the latest local and national guidelines for clinical practice.
References
Cooper JAL et al. Real-world performance of point-of-care metre, blood gas and laboratory glucose methods in Australian and American hospital inpatient cohorts. Diabet Med. 2026 Jun 17. doi: 10.1111/dme.70395. PMID: 42310492.
Mishra K et al. Accuracy of point-of-care capillary blood sugar measurements in critically ill patients: An observational study. Int J Crit Illn Inj Sci. 2024 Apr-Jun;14(2):74-78.
Tang Z et al. Validation of Point-of-Care Blood Glucose Monitoring Systems in Hospital Settings. Association for Diagnostics & Laboratory Medicine (ADLM). 2022.

A large-scale retrospective study reveals systematic biases in POC glucose meters compared to laboratory methods. Findings show that anaemia significantly amplifies negative bias at high glucose levels, suggesting a need for confirmatory testing in high-risk inpatient scenarios.
Today

Rucaparib (Rubraca) is the first FDA-approved PARP inhibitor for BRCA-mutated mCRPC. Evidence from the TRITON trials shows that it significantly improves radiographic progression-free survival compared to docetaxel, providing a potent and manageable oral alternative to standard chemotherapy.
Today

Nearly 80% of Indians suffer from inadequate Vitamin D, causing silent bone weakening and sudden fractures. This expert guide reviews why mega-dose therapy is critical for high-risk patients, the key factors driving widespread deficiency, and the mandatory medical evaluations needed to protect skeletal health.
Today

A new study by Pacific OneHealth Hospitals reveals that over 50% of millennials in Delhi-NCR are overweight or obese. It highlights a critical metabolic health risk window between ages 30 and 44, during which visceral fat accumulation and hypertension rise sharply, driving future cardiovascular diseases.
Today

This study explores atomic-scale techniques like PEALD to engineer ZnO-Chitosan biointerfaces for medical implants. These interfaces exhibit superior immunomodulatory properties and antiseptic activity against pathogens, marking a significant advancement for next-generation medical devices.
Today